JP2007513873A5 - - Google Patents

Download PDF

Info

Publication number
JP2007513873A5
JP2007513873A5 JP2006536183A JP2006536183A JP2007513873A5 JP 2007513873 A5 JP2007513873 A5 JP 2007513873A5 JP 2006536183 A JP2006536183 A JP 2006536183A JP 2006536183 A JP2006536183 A JP 2006536183A JP 2007513873 A5 JP2007513873 A5 JP 2007513873A5
Authority
JP
Japan
Prior art keywords
polypeptide
agent
antibody
expression
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006536183A
Other languages
English (en)
Japanese (ja)
Other versions
JP4764344B2 (ja
JP2007513873A (ja
Filing date
Publication date
Priority claimed from GB0324656A external-priority patent/GB0324656D0/en
Application filed filed Critical
Publication of JP2007513873A publication Critical patent/JP2007513873A/ja
Publication of JP2007513873A5 publication Critical patent/JP2007513873A5/ja
Application granted granted Critical
Publication of JP4764344B2 publication Critical patent/JP4764344B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2006536183A 2003-10-22 2004-10-22 卵巣癌に関与するタンパク質 Expired - Fee Related JP4764344B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0324656A GB0324656D0 (en) 2003-10-22 2003-10-22 A protein involved in ovarian cancer
GB0324656.8 2003-10-22
PCT/GB2004/004502 WO2005042102A1 (en) 2003-10-22 2004-10-22 A protein involved in ovarian cancer

Publications (3)

Publication Number Publication Date
JP2007513873A JP2007513873A (ja) 2007-05-31
JP2007513873A5 true JP2007513873A5 (https=) 2007-10-18
JP4764344B2 JP4764344B2 (ja) 2011-08-31

Family

ID=29595617

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006536183A Expired - Fee Related JP4764344B2 (ja) 2003-10-22 2004-10-22 卵巣癌に関与するタンパク質

Country Status (11)

Country Link
US (3) US20070009543A1 (https=)
EP (1) EP1677875B1 (https=)
JP (1) JP4764344B2 (https=)
AT (1) ATE470478T1 (https=)
AU (1) AU2004285339B2 (https=)
CA (1) CA2541846A1 (https=)
DE (1) DE602004027647D1 (https=)
ES (1) ES2347249T3 (https=)
GB (1) GB0324656D0 (https=)
PL (1) PL1677875T3 (https=)
WO (1) WO2005042102A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080008719A1 (en) * 2004-07-10 2008-01-10 Bowdish Katherine S Methods and compositions for the treatment of prostate cancer
AU2007210124A1 (en) * 2006-01-26 2007-08-09 The Trustees Of The University Of Pennsylvania Tumor vasculature markers and methods of use thereof
US20130136689A1 (en) * 2007-06-05 2013-05-30 Christian Rohlff Proteins
US8664358B2 (en) 2007-06-29 2014-03-04 Vermillion, Inc. Predictive markers for ovarian cancer
TWI412375B (zh) 2009-08-28 2013-10-21 Roche Glycart Ag 人類化抗cdcp1抗體
TW201113037A (en) 2009-08-28 2011-04-16 Hoffmann La Roche Antibodies against CDCP1 for the treatment of cancer
EP2971259B8 (en) 2013-03-13 2018-11-21 NantEnergy, Inc. Synergistic additives for electrochemical cells with electrodeposited fuel
WO2015082446A1 (en) 2013-12-02 2015-06-11 F. Hoffmann-La Roche Ag Treatment of cancer using an anti-cdcp1 antibody and a taxane
EP3554544A4 (en) 2016-12-16 2020-07-29 Bluefin Biomedicine, Inc. ANTI-PROTEIN 1 ANTIBODY CONTAINING AN ANTI-CUB DOMAIN (CDCP1), ANTIBODY-DRUG CONJUGATES AND THEIR METHODS OF USE
US11424484B2 (en) 2019-01-24 2022-08-23 Octet Scientific, Inc. Zinc battery electrolyte additive
EP4055058A4 (en) * 2019-11-06 2023-12-06 Commonwealth Scientific and Industrial Research Organisation BINDING OF PROTEINS TO THE DOMAIN CONTAINING PROTEIN (CDCP1)
JP7623705B2 (ja) 2019-12-27 2025-01-29 株式会社カイオム・バイオサイエンス 抗cdcp1抗体

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1100869A4 (en) 1998-07-30 2005-04-27 Human Genome Sciences Inc 98 HUMAN SECRETED PROTEINS
US7442776B2 (en) * 1999-10-08 2008-10-28 Young David S F Cancerous disease modifying antibodies
EP1301533A1 (de) 2000-07-07 2003-04-16 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Tumorassoziiertes antigen (b345), gekennzeichnet durch eine aminosäuresequenz wie in seq. id. no. 4
US20020142003A1 (en) * 2000-07-07 2002-10-03 Norbert Schweifer Tumor-associated antigen (B345)
US6783969B1 (en) 2001-03-05 2004-08-31 Nuvelo, Inc. Cathepsin V-like polypeptides
CN100422328C (zh) * 2003-02-19 2008-10-01 诺瓦提斯公司 在人转移性肿瘤细胞中表达的糖蛋白抗原sima135

Similar Documents

Publication Publication Date Title
JP6100822B2 (ja) プロカルシトニンの検出のためのイムノアッセイ
JP2021167805A (ja) SARS−CoV−2感染症を診断するための方法および試薬
EP2828282B1 (en) Biomarkers
JP2007513873A5 (https=)
JP2014506244A5 (https=)
JP2012515226A5 (https=)
JP2009544284A5 (https=)
JP2011501946A5 (https=)
Lévêque et al. Direct biosensor detection of botulinum neurotoxin endopeptidase activity in sera from patients with type A botulism
US7842456B2 (en) Reagents, kits and methods for immunodetection of epitopes on molecules
EP2332988A3 (en) Monoclonal antibodies and methods for their use in the detection of cervical disease
JP2005522228A5 (https=)
JP2021528411A5 (https=)
Snitkoff et al. Development of an immunoassay for monitoring the levels of ciprofloxacin patient samples
CN109313201B (zh) 用于监测细胞凋亡的特异于γ-谷氨酰基-L-ε-赖氨酸(GGEL)的单克隆抗体
US20220260593A1 (en) Targets and methods of diagnosing, monitoring and treating frontotemporal dementia
JP2008509082A5 (https=)
JPWO2024090571A5 (https=)
JP2005522229A5 (https=)
Morrissey et al. Kinetics of antigen− antibody interactions employing a MALDI mass spectrometry immunoassay
CA2771954A1 (en) Pneumonia biomarkers
EP3177312B1 (en) Method and kit for detecting bacterial infection
JP2008512391A5 (https=)
US20160216264A1 (en) Miox antibody and assay
Dvořák Preparation of affinity surfaces for microbiological diagnostics